These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 30197041)

  • 1. A Randomized, Double-blind, Phase II Trial of PSA-TRICOM (PROSTVAC) in Patients with Localized Prostate Cancer: The Immunotherapy to Prevent Progression on Active Surveillance Study.
    Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Kim HL; Nguyen MN; Gulley JL; Jamieson C; Hsu P; Wojtowicz M; Parnes H; Schlom J; Dahut WL; Madan RA; Donahue RN; Chow HS
    Eur Urol Focus; 2018 Sep; 4(5):636-638. PubMed ID: 30197041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of PROSTVAC immunotherapy in prostate cancer.
    Singh P; Pal SK; Alex A; Agarwal N
    Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Phase 2, Double-blind, Randomized Controlled Trial of PROSTVAC in Prostate Cancer Patients on Active Surveillance.
    Parsons JK; Pinto PA; Pavlovich CP; Uchio E; Nguyen MN; Kim HL; Gulley JL; Sater HA; Jamieson C; Hsu CH; Wojtowicz M; House M; Schlom J; Donahue RN; Dahut WL; Madan RA; Bailey S; Centuori S; Bauman JE; Parnes HL; Chow HS
    Eur Urol Focus; 2023 May; 9(3):447-454. PubMed ID: 36517408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PROSTVAC® targeted immunotherapy candidate for prostate cancer.
    Shore ND
    Immunotherapy; 2014; 6(3):235-47. PubMed ID: 24762070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer.
    Kantoff PW; Schuetz TJ; Blumenstein BA; Glode LM; Bilhartz DL; Wyand M; Manson K; Panicali DL; Laus R; Schlom J; Dahut WL; Arlen PM; Gulley JL; Godfrey WR
    J Clin Oncol; 2010 Mar; 28(7):1099-105. PubMed ID: 20100959
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for Localized Prostate Cancer: The Next Frontier?
    Patel D; McKay R; Parsons JK
    Urol Clin North Am; 2020 Nov; 47(4):443-456. PubMed ID: 33008495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dramatic and prolonged PSA response after retreatment with a PSA vaccine.
    Rojan A; Funches R; Regan MM; Gulley JL; Bubley GJ
    Clin Genitourin Cancer; 2013 Sep; 11(3):362-4. PubMed ID: 23791437
    [No Abstract]   [Full Text] [Related]  

  • 8. Immune impact induced by PROSTVAC (PSA-TRICOM), a therapeutic vaccine for prostate cancer.
    Gulley JL; Madan RA; Tsang KY; Jochems C; Marté JL; Farsaci B; Tucker JA; Hodge JW; Liewehr DJ; Steinberg SM; Heery CR; Schlom J
    Cancer Immunol Res; 2014 Feb; 2(2):133-41. PubMed ID: 24778277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
    DiPaola RS; Chen YH; Bubley GJ; Stein MN; Hahn NM; Carducci MA; Lattime EC; Gulley JL; Arlen PM; Butterfield LH; Wilding G
    Eur Urol; 2015 Sep; 68(3):365-71. PubMed ID: 25533418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current vaccination strategies for prostate cancer.
    Joniau S; Abrahamsson PA; Bellmunt J; Figdor C; Hamdy F; Verhagen P; Vogelzang NJ; Wirth M; Van Poppel H; Osanto S
    Eur Urol; 2012 Feb; 61(2):290-306. PubMed ID: 22001436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate cancer vaccines in clinical trials.
    Lubaroff DM
    Expert Rev Vaccines; 2012 Jul; 11(7):857-68. PubMed ID: 22913261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/IIa clinical trial of a novel hTERT peptide vaccine in men with metastatic hormone-naive prostate cancer.
    Lilleby W; Gaudernack G; Brunsvig PF; Vlatkovic L; Schulz M; Mills K; Hole KH; Inderberg EM
    Cancer Immunol Immunother; 2017 Jul; 66(7):891-901. PubMed ID: 28391357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure.
    Dreicer R; Stadler WM; Ahmann FR; Whiteside T; Bizouarne N; Acres B; Limacher JM; Squiban P; Pantuck A
    Invest New Drugs; 2009 Aug; 27(4):379-86. PubMed ID: 18931824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of biochemical recurrence of prostate cancer with granulocyte-macrophage colony-stimulating factor secreting, allogeneic, cellular immunotherapy.
    Urba WJ; Nemunaitis J; Marshall F; Smith DC; Hege KM; Ma J; Nguyen M; Small EJ
    J Urol; 2008 Nov; 180(5):2011-7; discussion 2017-8. PubMed ID: 18801509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
    Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
    Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy in prostate cancer.
    Sobol I; Thompson RH; Dong H; Krco C; Kwon ED
    Curr Urol Rep; 2015 Jun; 16(6):34. PubMed ID: 25894495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combining immunotherapies for the treatment of prostate cancer.
    Redman JM; Gulley JL; Madan RA
    Urol Oncol; 2017 Dec; 35(12):694-700. PubMed ID: 29146441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccine immunotherapy for prostate cancer: from mice to men.
    Lubaroff DM; Vaena D; Brown JA; Zehr P; Griffith KC; Brown E; Eastman J; Nepple K; Kattula A; Williams RD
    Immunol Res; 2014 Aug; 59(1-3):229-35. PubMed ID: 24847764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.